Generic Medicine Info
Lactation. Admin of yellow fever and other live attenuated vaccines.
Special Precautions
Patient w/ history of cirrhosis, hepatitis, alcoholism, CV events. Patients on radiotherapy. Hepatic (e.g. hepatic metastases) and renal impairment. Pregnancy. Prolonged infusion duration of >60 min or more frequent than wkly dosing may increase toxicity. Patient Counselling This drug may cause somnolence, if affected, do not drive or operate machinery. Monitoring Parameters Monitor CBC w/ differential and platelet count prior to each dose. Monitor pulmonary, hepatic, and renal function; electrolytes (i.e. K, Mg, Ca) when in combination therapy w/ cisplatin. Monitor for signs and symptoms of capillary leak syndrome and PRES.
Adverse Reactions
Significant: Bone marrow suppression manifested by neutropenia, thrombocytopaenia, and anaemia; capillary leak syndrome, posterior reversible encephalopathy syndrome (PRES). Nervous: Somnolence, flu-like symptoms, paraesthesia. CV: Peripheral oedema. GI: Nausea, vomiting, diarrhea, stomatitis, constipation. Resp: Dyspnoea. Hepatic: Transient liver enzyme elevations (e.g. AST, ALT, bilirubin, alkaline phosphatase). Genitourinary: Haematuria, proteinuria, increased BUN. Haematologic: Haemorrhage. Musculoskeletal: Myalgia. Dermatologic: Rash, pruritus, oedema, thrombocytopenic purpura, alopecia, peripheral vasculitis, gangrene. Immunologic: Infection. Others: Pain, fever, extravasation, injection site reaction.
Potentially Fatal: Severe hepatotoxicity (e.g. liver failure), pulmonary toxicity (e.g. pulmonary oedema, pulmonary fibrosis, interstitial pneumonitis, adult resp distress syndrome), ischaemic colitis w/ necrosis. Rarely, haemolytic uremic syndrome leading to renal failure.
Drug Interactions
May cause pulmonary toxicity w/ concurrent use of bleomycin. May enhance anticoagulant effect of warfarin.
CIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01BC05 - gemcitabine ; Belongs to the class of antimetabolites, pyrimidine analogues. Used in the treatment of cancer.
Disclaimer: This information is independently developed by CIMS based on gemcitabine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in